David Rosmarin
Overview
Explore the profile of David Rosmarin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shah M, Burshtein J, Zakria D, Boh E, Cameron M, Glick B, et al.
J Drugs Dermatol
. 2025 Feb;
24(2):147-155.
PMID: 39913225
Background: Psoriasis is a chronic, inflammatory disease associated with numerous negative physical and psychosocial impacts. Deucravacitinib is a novel, selective TYK2 inhibitor approved by the FDA for the treatment of...
2.
Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong H, et al.
J Am Acad Dermatol
. 2024 Dec;
PMID: 39733939
Background: Lebrikizumab demonstrated statistically significant improvements in patients with moderate-to-severe atopic dermatitis at week 16 with a durable response up to week 52. Objective: To investigate the efficacy of lebrikizumab-treated...
3.
Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb A, et al.
J Am Acad Dermatol
. 2024 Dec;
PMID: 39709077
Background: Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in patients with obese. The purpose of this expert consensus panel is...
4.
Harris J, Pandya A, Lebwohl M, Hamzavi I, Grimes P, Gottlieb A, et al.
Skin Health Dis
. 2024 Dec;
4(6):e404.
PMID: 39624731
No abstract available.
5.
Thyssen J, Rosmarin D, Costanzo A, Warren R, Chu C, Chovatiya R, et al.
Dermatology
. 2024 Oct;
241(1):10-18.
PMID: 39476813
Introduction: Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity Index (EASI)....
6.
Silverberg J, Rosmarin D, Chovatiya R, Bieber T, Schleicher S, Beck L, et al.
Nat Commun
. 2024 Oct;
15(1):9230.
PMID: 39455575
Regulatory T cell (Treg) impairment is implicated in the pathogenesis of chronic inflammatory diseases, but relatively little is known about the therapeutic potential of Treg restoration. Here we present clinical...
7.
Ezzedine K, Wolkerstorfer A, Wei S, Korba A, Kornacki D, Rosmarin D
J Eur Acad Dermatol Venereol
. 2024 Oct;
PMID: 39417427
No abstract available.
8.
Encarnacion-Cortes V, Rodriguez I, Rinderknecht F, Admassu N, Phillips G, Castillo-Valladares H, et al.
Cutis
. 2024 Oct;
114(3):72-75.
PMID: 39413328
Current dermatology residency education may be deficient in curricular topics and training related to diversity, equity, and inclusion (DEI). Integrating more DEI topics within residency curricula may improve clinical care...
9.
Renert-Yuval Y, Desai S, Huang V, Walsh S, Rosmarin D, Silverberg N
J Drugs Dermatol
. 2024 Oct;
23(10):842-846.
PMID: 39361696
Background: The literature on vitiligo is heterogeneous with limited standardization in vitiligo disease severity reporting. Objectives: The IDEOM Vitiligo Workgroup initiated a project to develop an improved understanding of clinical...
10.
Learned C, Alsukait S, Fiumara K, Ortega M, Chambers J, Rosmarin D
J Psoriasis Psoriatic Arthritis
. 2024 Sep;
7(4):160-163.
PMID: 39296962
Background: Specialty medications provide effective treatment with limited adverse effects to patients with psoriasis and psoriatic arthritis; however, variable coverage and high costs often create a barrier to treatment for...